DNTH Stock Forecast & Price Target

Dianthus Therapeutics is viewed positively because it is building a differentiated autoimmune franchise around claseprubart and the internally developed DNTH312, a first-in-class bifunctional fusion protein that combines complement and B-cell inhibition across validated disease pathways. The company’s scientific edge is reinforced by preclinical data showing DNTH312 matched claseprubart’s complement inhibition, delivered up to 58% IgA reduction in NHPs, and may offer a roughly 4x longer half-life, while its IP could extend at least to 2047 and preserve better economics. Financially, the balance sheet appears strong with $1.2B in cash and runway beyond pivotal claseprubart readouts, supporting a broader three-asset pipeline with MMN top-line data on track for December 2026 and a potential clinical start for DNTH312 by YE27.

Dianthus Therapeutics is viewed negatively because its shares remain highly exposed to competitive read-throughs, where rival clinical or regulatory progress could quickly weaken sentiment around its pipeline. The company also faces a clear financing risk, as it will need to access capital markets to fund development and eventual commercialization, and failure to secure adequate capital could impede pipeline advancement. In addition, regulatory uncertainty is material: accelerated approval strategies may still require extra data or longer studies, and an unfavorable label could limit market traction for Claseprubart and other assets.